These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
Generic name: nirogacestat hydrobromide
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 23, 2024
Generic Entry Controlled by: Dominican Republic Patent P2005000040
Patent Title: COMPUESTOS DE IMIDAZOL PARA EL TRATAMIENTO DE TRASTORNOS NEURODEGENERATIVOS
OGSIVEO is a drug marketed by Springworks. There are twelve patents protecting this drug.
This drug has sixty-five patent family members in forty-four countries.
See drug price trends for OGSIVEO.
The generic ingredient in OGSIVEO is nirogacestat hydrobromide. One supplier is listed for this generic product. Additional details are available on the nirogacestat hydrobromide profile page.
Generic name: sorafenib tosylate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: March 07, 2025
Generic Entry Controlled by: Dominican Republic Patent P2006000057
Patent Title: COMPOSICIÓN FARMACEÚTICA PARA EL TRATAMIENTO DEL CÁNCER
NEXAVAR is a drug marketed by Bayer Hlthcare. There are three patents protecting this drug and one Paragraph IV challenge.
This drug has one hundred and four patent family members in thirty-nine countries. There has been litigation on patents covering NEXAVAR
See drug price trends for NEXAVAR.
The generic ingredient in NEXAVAR is sorafenib tosylate. There are thirteen drug master file entries for this API. Nine suppliers are listed for this generic product. Additional details are available on the sorafenib tosylate profile page.
DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.